HHS watchdog office steps up focus on drug pricing
(By Ed Silverman for ST A T) S eeking to address rising concerns about prescription medicines, the watchdog arm of
Read More
Part D/Prescription Drugs
Background Information on Medicare Plans to Help You Make a Choice
In Karen Tellen-Lawton’s column, she gives a little background information on Medicare in effort to help the reader to understand
Read MoreTrump, GOP In Congress Could Use “Must-Pass” Bills To Bring Health Changes
(By Julie Rovner for Kaiser Health News) Throughout the campaign, President-Elect Donald Trump’s entire health message consisted of promising to
Read MoreBig Pharma’s big question: Is Trump friend or foe?
(By Dylan Scott for ST A T) W ASHINGTON — Should President Donald Trump make drug makers relieved? Or anxious?
Read MoreNovel system to get dying patients an experimental cancer drug raises hopes — and thorny questions
(By Karen Weintraub for ST A T) T he drug was still experimental, but clinical trials suggested it could be
Read MoreSupreme Court lets pay-to-delay ruling against pharma stand
(By Ed Silverman for ST A T) C ash is not always king. In a move that should settle a
Read MoreCalifornia’s Drug Price Initiative: Will Voters ‘Send A Signal To Washington’?
(By Pauline Bartolone for California Healthline) This year, Mary O’Connor and her father made voting a family affair. O’Connor’s father
Read MoreThis drug discount program is good for Americans. But pharma wants to gut it
(By Ted Slafsky for ST A T) S ticker shock over the cost of drugs isn’t going away any time
Read MoreHealth officials find first cases of new superbug in US
(By Sharon Begley for ST A T) J ust five months after federal health officials asked hospitals and physicians to
Read MoreWhat clinical trial results? Now you can see who isn’t sharing their findings
(By Ed Silverman for ST A T) T he results for nearly half of all clinical trials conducted by big
Read More